ArticleCancer medicine2026
The Prognostic Value of Serum Inflammatory Markers in Nasopharyngeal Carcinoma Patients Treated With Immune Checkpoint Inhibitors: A Multicenter Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAlthough immune checkpoint inhibitors (ICIs) have revolutionized the treatment of nasopharyngeal carcinoma (NPC), reliable predictive biomarkers need to be further explored. This study aimed to investigate the predictive ability of inflammatory markers for poor prognosis in NPC patients treated with ICIs.
methodsIn this multicenter retrospective study, a total of NPC patients treated with at least two cycles of ICIs from May 2019 to December 2022 at three independent medical centers in China were included. In this study, we collected the multiple hematological parameters from patients prior to treatment to calculate serum inflammatory markers, and we performed the multivariate COX analysis to identify independent prognostic factors for constructing columnar plots. Then the ROC survival curves, calibration curves, and clinical curve analysis were used to assess the predictive performance of the model.
resultsA total of 170 patients were included in the training group with a median follow-up of 26 months. Univariate and multivariate Cox regression analyses showed that Hb, Prognostic Nutritional Index (PNI), and the number of metastases were independent prognostic factors for overall survival (OS). A nomogram was constructed based on these three factors to predict the prognosis of NPC patients after ICI treatment. The nomogram achieved a C-index of 0.733 in the training cohort and 0.743 in the validation cohort, indicating good discriminative ability. Time-dependent ROC curves demonstrated favorable predictive accuracy, with area under the curve (AUC) values for 1-, 2-, and 3-year OS of 0.701, 0.756, and 0.760 in the training set, and 0.773, 0.784, and 0.777 in the validation set. The model was further validated using calibration plots and decision curve analysis (DCA), and patients were categorized into high- and low-risk groups, with the validation cohort also showing consistent survival differentiation.
conclusionThe combination of serum inflammatory markers and clinicopathological factors may serve as a practical prognostic tool to predict NPC patients who may benefit from ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.